Literature DB >> 24347490

USP28 is a potential prognostic marker for bladder cancer.

Guiying Guo1, Yangyang Xu, Mancheng Gong, Yan Cao, Ruihua An.   

Abstract

This study was conducted to analyze the expression of the ubiquitin-specific protease Usp28 and assess its clinical significance in human bladder cancer. mRNA and protein expression levels of Usp28 were determined by real-time polymerase chain reaction (PCR) and Western blot in 24 paired bladder cancers and the adjacent non-cancerous tissues. In addition, the expression of Usp28 protein in 186 bladder cancers was also determined by immunohistochemistry. The relationship between expression of Usp28 and clinico-pathologic features and prognosis was finally evaluated. Usp28 was expressed at a higher level in bladder cancers compared to adjacent non-cancerous tissues at both the mRNA and protein levels in 24 paired samples (all P < 0.01). In immunohistochemical examination, 78 (41.9%) of 186 cases displayed low Usp28 expression in cancerous tissues, whereas 108 (58.1%) cases displayed high Usp28 expression. In the universal analysis, Usp28 correlated strongly with histopathological grade, clinical stage, tumor number and recurrence rate (P = 0.0001, 0.0001, 0.0001 and 0.0051, respectively), but did not correlate with gender or age (P = 0.5588 and 0.6574). After multiple analysis of the above factors and consideration of confounding factors, tumor number, histological grade, clinical stage, and recurrence were related to Usp28 expression (P = 0.001, 0.001, 0.001 and 0.001, respectively). Finally, Usp28 expression was indentified as a independent predictors of survival (P = 0.001). Usp28 protein expression is potentially valuable in prognostic evaluation of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24347490     DOI: 10.1007/s13277-013-1525-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

3.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover.

Authors:  F Bahram; N von der Lehr; C Cetinkaya; L G Larsson
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

4.  The database dbEST correctly predicts gene expression in colon cancer patients.

Authors:  M Radeva; T Hofmann; B Altenberg; H Mothes; K K Richter; B Pool-Zobel; K O Greulich
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.

Authors:  Antonio Garcia-España; Edgard Salazar; Tung-Tien Sun; Xue-Ru Wu; Angel Pellicer
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 8.  Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.

Authors:  Sanaa Eissa; Samar Kassim; Omar El-Ahmady
Journal:  Curr Opin Obstet Gynecol       Date:  2003-10       Impact factor: 1.927

9.  Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.

Authors:  S E Salghetti; S Y Kim; W P Tansey
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

10.  The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival.

Authors:  A Peschiaroli; J R Skaar; M Pagano; G Melino
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more
  10 in total

1.  Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression.

Authors:  Zengwu Wang; Qimin Song; Jian Xue; Yumei Zhao; Shiqiang Qin
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-23

2.  CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.

Authors:  Xi Zhu; Yan Qiao; Weihua Liu; Wenying Wang; Hongliang Shen; Yi Lu; Gangyue Hao; Jiajia Zheng; Ye Tian
Journal:  Tumour Biol       Date:  2015-10-27

Review 3.  Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes.

Authors:  Hae-Seul Choi; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

Review 4.  DUBs, New Members in the Hypoxia Signaling clUb.

Authors:  Amelie S Schober; Edurne Berra
Journal:  Front Oncol       Date:  2016-03-09       Impact factor: 6.244

Review 5.  Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-α Subunit Abundance.

Authors:  Kateryna Kubaichuk; Thomas Kietzmann
Journal:  Cells       Date:  2019-06-15       Impact factor: 6.600

Review 6.  The paradoxical roles of miR-4295 in human cancer: Implications in pathogenesis and personalized medicine.

Authors:  Yin Li; Yihan Zhang; Yuhao Zou; Shiwei Duan
Journal:  Genes Dis       Date:  2020-10-06

7.  Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Pei-Gen Xie; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-09-04

Review 8.  DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets.

Authors:  Adan Pinto-Fernandez; Benedikt M Kessler
Journal:  Front Genet       Date:  2016-07-28       Impact factor: 4.599

Review 9.  Targeting deubiquitinase USP28 for cancer therapy.

Authors:  Xiaofang Wang; Zhiyi Liu; Li Zhang; Zhaozhi Yang; Xingxing Chen; Jurui Luo; Zhirui Zhou; Xin Mei; Xiaoli Yu; Zhimin Shao; Yan Feng; Shen Fu; Zhen Zhang; Dongping Wei; Lijun Jia; Jinli Ma; Xiaomao Guo
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

Review 10.  Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.

Authors:  Ainsley Mike Antao; Apoorvi Tyagi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.